Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
The main purpose of this study is to determine the safe and efficacy of APR-246 in combination with azacitidine as well as to see complete remission of this patients
Myelodysplastic Syndrome With Gene Mutation|Acute Myeloid Leukemia With Gene Mutations|Myeloproliferative Neoplasm|Chronic Myelomonocytic Leukemia
DRUG: APR-246|DRUG: Azacitidine
Overall Survival, overall survival at complete remission, 8 months
Duration of response, minimum 24 months it is defined as the time between achieving response and progression of disease
Patients will be treated for a total of 6 cycles.For patients responding or who have stable disease following cycle 6, treatment may continue until one of the following criteria applies:

* Inter-current illness that prevent further administration of treatment
* Unacceptable adverse event(s)
* Participant decides to withdraw from the study,
* general or specific changes in the participant's condition render the participant unacceptable for further treatment in the judgment of the investigator.
* Evidence of disease progression by international working Group (IWG) 2006 criteria.
* participants who wish not to continue treatment at time of disease assessment at end of cycle 6 will complete their end of treatment visit upon completion of cycle 6